On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

NCT01670162 | Unknown Phase 4

• 1 other identifier: VGFT-OD-1220
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.

Conditions

Age Related Macular Degeneration; Pigment Epithelial Detachment

Keywords

Pigment Epithelium of Eye; Wet macular degeneration; Macular degeneration

Outcome Measures

Primary Outcomes (1)

• Proportion of patients with flattening of PED

  12 months

Secondary Outcomes (10)

• Mean Change in Best Corrected Visual Acuity (BCVA)

  6 month timepoint and 12 month timepoints

• Proportion of patients with flattening of PED

  6 months

• Proportion of patients with flattening of PED

  18 month and 24 month timepoints

• Mean number of injections needed

  12 month period

• Mean change in Optical Coherence Tomography (OCT) central retinal thickness

  6 month and 12 month timepoints

Other Outcomes (1)

• Incidence and severity of adverse events

  24 month period

Study Arms (1)

3 loading doses, then every 2 months

EXPERIMENTAL

All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.

Drug: Aflibercept

Interventions

Aflibercept DRUG

Intravitreal Injection 2mg/0.05mL Aflibercept

Also known as: VEGF-Trap, Eylea

3 loading doses, then every 2 months

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Previous enrollment in the study evaluating 2.0mg ranibizumab (NCT 01189019) without early study discontinuation. The last treatment\* in the study eye should have been received at least 30 days before enrollment in this study.
• \*\*last study treatment of either 1.0mg or 2.0mg ranibizumab
• Presence of persistent fibrovascular pigment epithelial detachment Willing and able to comply iwth clinic visits and study related procedures Provide signed informed consent

You may not qualify if:

• Prior treatment with verteporfin, or external beam radiation therapy, or transpupillary thermotherapy in the study eye.
• Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye.
• History of vitrectomy, submacular surgery, or other surgical intervention for AMD in the study eye.
• Concurrent eye disease in the study eye that could compromise visual acuity (e.g. diabetic retinopathy, advanced glaucoma).
• Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy or glaucoma) that, in the opinion of the investigator, could either require medical or surgical intervention during the 12 month study period to prevent or treat visual loss that might result from that condition, or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 12 month study period.
• Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or auto-immune associated uveitis in either eye.
• Current vitreous hemorrhage in the study eye.
• History of rhegmatogenous retinal detachment or macular hole (stage 3 or 4) in the study eye.
• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
• Aphakia, anterior chamber intraocular lens (ACIOL) or unstable posterior chamber intraocular lens (PCIOL).
• Uncontrolled glaucoma in the study eye (defined as intraocular pressure equal to or greater than 30 despite treatment with anti-glaucoma medication).
• Pregnant or breastfeeding women.
• Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraception measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam or jelly).
• Contraception is not required for men with documented vasectomy. \*\*Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Sponsors & Collaborators

• Tennessee Retina: lead
• Regeneron Pharmaceuticals: collaborator

Study Sites (3)

Pacific Eye Associates

San Francisco, California, 94115, United States

Location

Retina Associates of Kentucky

Lexington, Kentucky, 40509, United States

Location

Tennessee Retina, P.C.

Nashville, Tennessee, 37203, United States

Location

MeSH Terms

Conditions

Macular Degeneration; Retinal Detachment; Wet Macular Degeneration

Interventions

aflibercept

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases

Study Officials

• Brandon G Busbee, MD

  Tennessee Retina, PC

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 17, 2012
• First Posted: August 21, 2012
• Study Start: August 1, 2012
• Primary Completion: November 1, 2015
• Study Completion: January 1, 2016
• Last Updated: October 29, 2014

Record last verified: 2014-10

Locations

US (3)